Is xgeva for bone loss?

What is Xgeva?

Xgeva is a medication used to prevent bone loss in certain types of cancers, such as multiple myeloma or breast cancer, that have spread to the bone [1]. It is a type of bisphosphonate, which works by inhibiting the activity of osteoclasts, the cells responsible for breaking down bone tissue [2].

How does Xgeva work?

Xgeva is administered via injection, and it works by binding to osteoclasts, preventing them from resorbing bone tissue. This helps maintain bone mineral density, reducing the risk of bone fractures and other complications associated with bone loss [3].

Who is Xgeva for?

Xgeva is typically prescribed for patients with cancer that has spread to the bone, as well as those undergoing treatments that may cause bone loss. It is specifically approved for use in multiple myeloma and bone metastases from solid tumors, such as breast, prostate, and lung cancer [4].

Can Xgeva be used for bone loss in general?

While Xgeva is primarily designed for cancer patients, it can be used to prevent bone loss in other conditions, such as osteoporosis, as long as the patient meets specific criteria, such as having a high risk of fracture or certain comorbidities [5].

Are there risks associated with Xgeva use?

Like other bisphosphonates, Xgeva may have risks, including jaw bone necrosis, esophagitis, and atrial fibrillation. Patients taking Xgeva should have regular dental check-ups and inform their healthcare provider if they experience any symptoms [6].

Sources

[1] Amgen. (2022). XGEVA Prescribing Information.

[2] National Cancer Institute. (2022). Xgeva.

[3] DrugPatentWatch.com. (2022). Xgeva patent information.

[4] Food and Drug Administration. (2010). Xgeva approved for use in patients with multiple myeloma and bone metastases from solid tumors.

[5] ClinicalTrials.gov. (2022). A Study of Xgeva for Osteoporosis.

[6] FDA. (2022). Xgeva and the risk of jaw bone necrosis.